Drug Profile

Research programme: coronavirus therapeutics - Ginkgo Bioworks

Alternative Names: WDB-002

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Warp Drive Bio
Developer Ginkgo Bioworks
Class Alkenes; Amides; Antivirals; Esters; Ketones; Pyrans; Pyridines; Small molecules
Mechanism of Action CEP250 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA
30 Jun 2020 WDB 002 and its related compounds licensed to Ginkgo Bioworks for COVID-2019 infections
30 Jun 2020 Preclinical trials in COVID-2019 infections in USA (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com